title: FimH, a TLR4 ligand, induces innate antiviral responses in the lung leading to protection against lethal influenza infection in mice.
abstract: Fimbriae H protein (FimH) is a novel TLR4 ligand that has been shown to stimulate the innate immune system and elicits protective responses against bacterial and viral infections. Here, we evaluated the protective role of local delivery of FimH against influenza A infection in a mouse model. We show that intranasal delivery of FimH prior to lethal challenge with influenza A virus, resulted in decreased morbidity and mortality in wild-type, but not TLR4(-/-), mice. Importantly, FimH was able to reduce the early viral burden in the lung leading to minimal cell infiltration into the airway lumen and reduced pulmonary pathology following infection in wild type mice compared to TLR4(-/-) mice. Local delivery of FimH to C57BL/6, not TLR4(-/-), mice in a prophylactic manner increased the IL-12 and RANTES responses as well as neutrophil recruitment into the airway lumen. These effects correlate to the course of influenza infection. The FimH-mediated antiviral response against influenza virus appears to be partially dependent on alveolar macrophages. The antiviral effects are likely mediated by the innate mediators (TNF-α, IL-12 or RANTES) and/or by activation of a feedback inhibition loop to curtail the pulmonary inflammation possibly be the potential mechanisms involved in FimH-mediated protection. FimH thus holds promise to be a possible prophylactic mean of control against influenza viral infection.
authors.affiliation: Center for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University Health Sciences Center, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5.
authors.forename: Mohamed F
authors.initials: MF
authors.lastname: Abdul-Careem
authors.forename: M
authors.initials: M
authors.lastname: Firoz Mian
authors.forename: Amy E
authors.initials: AE
authors.lastname: Gillgrass
authors.forename: Meghan J
authors.initials: MJ
authors.lastname: Chenoweth
authors.forename: Nicole G
authors.initials: NG
authors.lastname: Barra
authors.forename: Tiffany
authors.initials: T
authors.lastname: Chan
authors.forename: Amal A
authors.initials: AA
authors.lastname: Al-Garawi
authors.forename: Marianne V
authors.initials: MV
authors.lastname: Chew
authors.forename: Geoffry
authors.initials: G
authors.lastname: Yue
authors.forename: Nico
authors.initials: N
authors.lastname: van Roojen
authors.forename: Zhou
authors.initials: Z
authors.lastname: Xing
authors.forename: Ali A
authors.initials: AA
authors.lastname: Ashkar
mesh_terms: D018830:Adhesins, Escherichia coli / Q000008:administration & dosage* / Q000276:immunology*; D000281:Administration, Intranasal; D000818:Animals; D002465:Cell Movement; D018946:Chemokine CCL5 / Q000378:metabolism; D036781:Fimbriae Proteins / Q000008:administration & dosage* / Q000276:immunology*; D007113:Immunity, Innate / Q000187:drug effects*; D009980:Influenza A virus / Q000276:immunology / Q000472:pathogenicity; D018664:Interleukin-12 / Q000378:metabolism; D008168:Lung / Q000473:pathology / Q000821:virology; D016676:Macrophages, Alveolar / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009504:Neutrophils / Q000276:immunology; D009976:Orthomyxoviridae Infections / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D016019:Survival Analysis; D051197:Toll-Like Receptor 4 / Q000008:administration & dosage* / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D018830:Adhesins, Escherichia coli; D018946:Chemokine CCL5; C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4; D014409:Tumor Necrosis Factor-alpha; C058769:fimH protein, E coli; D036781:Fimbriae Proteins; D018664:Interleukin-12